Reducing harm from tobacco use

Journal of Psychopharmacology

Volumn 27, Issue 1, 2013, Pages 13-18

  McNeill, Ann ^a   Munafò, Marcus R ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EXCIPIENT; NICOTINE;

AWARENESS; CANCER RISK; CARDIOVASCULAR RISK; DRUG DELIVERY SYSTEM; ELECTRONICS; GOVERNMENT REGULATION; HEALTH EDUCATION; HEALTH HAZARD; HUMAN; NICOTINE REPLACEMENT THERAPY; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION; SMOKELESS TOBACCO; SMOKING CESSATION PROGRAM; SOCIAL MARKETING; TOBACCO DEPENDENCE; UNITED KINGDOM;

HARM REDUCTION; HUMANS; PUBLIC HEALTH; SMOKING; STREET DRUGS; TOBACCO; TOBACCO USE DISORDER;

EID: 84871597636     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881112458731     Document Type: Review

References (29)

1. Alderman J, Dollar KM, Kozlowski LT. Understanding the origins of anger, contempt and disgust in public health policy disputes: Applying moral psychology to harm reduction debates. J Public Health Policy. 2010 ; 1: 1-16
2. ASH (2008) Beyond smoking kills: Protecting children, reducing inequalities. Available at: http://www.ash.org.uk/beyondsmokingkills (17 July 2012).
3. ASH (2010) YouGov survey of electronic cigarette users. Available at: http://ash.org.uk/files/documents/ASH-739.pdf (accessed 25 April 2012).
4. Beard E, McNeill A, Aveyard P, et al. Use of nicotine replacement therapy for smoking reduction and during enforced temporary abstinence: A national survey of English smokers. Addiction. 2011 ; 106: 197-204
5. Bertuccio P, La Vecchia C, Silverman DT, et al. Cigar and pipe smoking, smokeless tobacco use and pancreatic cancer: An analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol. 2011 ; 22: 1420-1426
6. Boffeta P, Hecht S, Gray N, et al. Smokeless tobacco and cancer. Lancet Oncology. 2008 ; 9: 667-675
7. Etter JF, Bullen C. Saliva cotinine levels in users of electronic cigarettes. Eur Respir J. 2011 ; 38: 1219-1220
8. Eurostat Database. Available at: http://epp.eurostat.ec.europa.eu (accessed 5 March 2012).
9. European Commission Scientific Committee of Emerging and Newly Identified Health Risks (SCENIHR) (2008) Health effects of smokeless tobacco products. Available at: http://ec.europa.eu/health/ph-risk/committees/04-scenihr/docs/ scenihr-o-013.pdf (17 July 2012).
10. Foulds JL, Ramstrom L, Burke M, et al. Effect of smokeless tobacco (snus) on smoking and public health in Sweden. Tobacco Control. 2003 ; 12: 349-359
11. Gartner CE, Hall WD, Vos T, et al. Assessment of Swedish snus for tobacco harm reduction: An epidemiological modelling study. Lancet. 2007 ; 369: 2010-2014
12. Hammond D, Reid JL, Driezen P, et al. Smokers' use of nicotine replacement therapy for reasons other than stopping smoking: Findings from the ITC Four Country Survey. Addiction. 2008 ; 103: 1696-1703
13. Kozlowski LT, Straser AA, Giovino GA, et al. Applying the risk/use equilibrium: Use medicinal nicotine now for harm reduction. Tobacco Control. 2001 ; 10: 201-203
14. Langley TE, Huang Y, Lewis S, et al. Prescribing of nicotine replacement therapy in adolescents in England. Addiction. 2011 ; 106: 1513-9.
15. Langley TE, Szatkowski L, McNeill A, et al. Prescribing of nicotine replacement therapy to cardiovascular disease patients in England. Addiction. 2012 ; 107: 1341-1348
16. Lee PN, Hamling J. Systematic review of the relation between smokeless tobacco and cancer in Europe and North America. BMC Medicine. 2009 ; 7: 36
17. Levy DT, Mumford EA, Cummings KM, et al. The relative risks of a low-nitrosamine smokeless tobacco product compared with smoking cigarettes: Estimates of a panel of experts. Cancer Epidemiol Biomarkers Prev. 2004 ; 13: 2035-2042
18. Lund K, Scheffels J, McNeill A. Association between use of snus and quit rates for smoking: Results from seven Norwegian crosssectional studies. Addiction. 2010 ; 106: 162-167
19. McNeill A, Foulds J, Bates C. Regulation of nicotine replacement therapies (NRT). A critique of current practice. Addiction. 2001 ; 96: 1757-1768
20. McNeill A, Hammond D, Gartner C. Whither product regulation?. Tobacco Control. 2012 ; 21: 221-226
21. Murray RP, Bailey WC, Daniels K, et al. Safety of nicotine polacrilex gum used by 2,094 participants in the Lung Health Study. Lung Health Study Research Group. Chest. 1996 ; 109: 438-445
22. Murray RP, Bailey WC, Daniels K, et al. Safety of nicotine polacrilex gum used by 2,094 participants in the Lung Health Study. Lung Health Study Research Group. Chest. 1996 ; 109: 438-445
23. London: NICE ; 2008 :
24. Regan AK, Promoff G, Dube SR, et al. Electronic nicotine delivery systems: Adult use and awareness of the 'e-cigarette' in the USA. Tobacco Control. 2011 ;:
25. Report of the Tobacco Advisory Group of the Royal College of Physicians. London: Royal College of Physicians of London ; 2000 :
26. Report of the Tobacco Advisory Group of the Royal College of Physicians. London: Royal College of Physicians of London ; 2007 :
27. Siahpush M, McNeill A, Fong G, et al. Socioeconomic and country variations in knowledge of health risks of tobacco smoking and toxic constituents of smoke. Results from the 2002 International Tobacco Control Policy Evaluation Survey. Tobacco Control. 2006 ; 15: 65-70
28. Stenbeck M, Hagquist C, Rosen M. The association of snus and smoking behaviour: A cohort analysis of Swedish males in the 1990s. Addiction. 2009 ; 1004: 1579-1585
29. Stratton K Shetty P Wallace Robert, ed. Washington, DC: National Academy Press ; 2001 :